{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:44:03Z","timestamp":1787499843380,"version":"build-2736575974"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s12012-024-09834-9","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T08:02:47Z","timestamp":1707292967000},"page":"184-198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Management of Fluoropyrimidine-Induced Cardiac Adverse Outcomes Following Cancer Treatment"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3146-1144","authenticated-orcid":false,"given":"Mohsen","family":"Rajaeinejad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3521-0959","authenticated-orcid":false,"given":"Peyvand","family":"Parhizkar-Roudsari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehran","family":"Khoshfetrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hassan","family":"Kazemi-galougahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Mosaed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasta","family":"Arjmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Abolfazl","family":"Mohsenizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5001-5006","authenticated-orcid":false,"given":"Babak","family":"Arjmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"issue":"4","key":"9834_CR1","first-page":"309","volume":"66","author":"G Curigliano","year":"2016","unstructured":"Curigliano, G., Cardinale, D., Dent, S., Criscitiello, C., Aseyev, O., Lenihan, D., & Cipolla, C. M. (2016). Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA: A Cancer Journal for Clinicians, 66(4), 309\u2013325.","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"3","key":"9834_CR2","first-page":"302","volume":"4","author":"C Porter","year":"2022","unstructured":"Porter, C., Azam, T. U., Mohananey, D., Kumar, R., Chu, J., Lenihan, D., Dent, S., Ganatra, S., Beasley, G. S., & Okwuosa, T. (2022). Permissive cardiotoxicity: The clinical crucible of cardio-oncology. JACC: CardioOncology, 4(3), 302\u2013312.","journal-title":"JACC: CardioOncology"},{"issue":"1","key":"9834_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1186\/s12885-017-3505-0","volume":"17","author":"A Skitch","year":"2017","unstructured":"Skitch, A., Mital, S., Mertens, L., Liu, P., Kantor, P., Grosse-Wortmann, L., Manlhiot, C., Greenberg, M., & Nathan, P. C. (2017). Novel approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer: a multi-centre observational study. BMC Cancer, 17(1), 519.","journal-title":"BMC Cancer"},{"issue":"20","key":"9834_CR4","doi-asserted-by":"publisher","first-page":"7802","DOI":"10.3390\/ijms21207802","volume":"21","author":"V Quagliariello","year":"2020","unstructured":"Quagliariello, V., De Laurentiis, M., Cocco, S., Rea, G., Bonelli, A., Caronna, A., Lombari, M. C., Conforti, G., Berretta, M., Botti, G., & Maurea, N. (2020). NLRP3 as putative marker of ipilimumab-induced cardiotoxicity in the presence of hyperglycemia in estrogen-responsive and triple-negative breast cancer cells. International Journal of Molecular Sciences, 21(20), 7802.","journal-title":"International Journal of Molecular Sciences"},{"key":"9834_CR5","unstructured":"Quagliariello, V., Paccone, A., Iovine, M., Cavalcanti, E., Berretta, M., Maurea, C., Canale, M.L., Maurea, N. (2021). Interleukin-1 blocking agents as promising strategy for prevention of anticancer drug-induced cardiotoxicities: Possible implications in cancer patients with COVID-19. European Review for Medical & Pharmacological Sciences. 25(21)."},{"issue":"4","key":"9834_CR6","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/annonc\/mdh150","volume":"15","author":"T S\u00fcdhoff","year":"2004","unstructured":"S\u00fcdhoff, T., Enderle, M. D., Pahlke, M., Petz, C., Teschendorf, C., Graeven, U., & Schmiegel, W. (2004). 5-Fluorouracil induces arterial vasocontractions. Annals of Oncology, 15(4), 661\u2013664.","journal-title":"Annals of Oncology"},{"issue":"10","key":"9834_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-251016","volume":"15","author":"K Boldig","year":"2022","unstructured":"Boldig, K., Ganguly, A., Kadakia, M., & Rohatgi, A. (2022). Managing life-threatening 5-fluorouracil cardiotoxicity. BMJ Case Reports CP, 15(10), e251016.","journal-title":"BMJ Case Reports CP"},{"key":"9834_CR8","unstructured":"Pallavi, N. (2020). The cardiotoxicity of chemotherapy."},{"key":"9834_CR9","doi-asserted-by":"publisher","first-page":"885699","DOI":"10.3389\/fphar.2022.885699","volume":"13","author":"Y Lu","year":"2022","unstructured":"Lu, Y., Deng, S., Dou, Q., Pan, W., Liu, Q., Ji, H., Wang, X., & Zhang, H. M. (2022). Treatment-related coronary disorders of fluoropyrimidine administration: A systematic review and meta-analysis. Frontiers in Pharmacology, 13, 885699.","journal-title":"Frontiers in Pharmacology"},{"issue":"5","key":"9834_CR10","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/annonc\/mdu055","volume":"25","author":"C Lestuzzi","year":"2014","unstructured":"Lestuzzi, C., Vaccher, E., Talamini, R., Lleshi, A., Meneguzzo, N., Viel, E., Scalone, S., Tartuferi, L., Buonadonna, A., Ejiofor, L., & Schmoll, H. J. (2014). Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 25(5), 1059\u20131064.","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology"},{"issue":"3","key":"9834_CR11","doi-asserted-by":"publisher","first-page":"e403","DOI":"10.1002\/onco.13536","volume":"26","author":"A Dyhl-Polk","year":"2020","unstructured":"Dyhl-Polk, A., Schou, M., Vistisen, K. K., Sillesen, A. S., Serup-Hansen, E., Faber, J., Klausen, T. W., Bojesen, S. E., Vaage-Nilsen, M., & Nielsen, D. L. (2020). Myocardial ischemia induced by 5-fluorouracil: A prospective electrocardiographic and cardiac biomarker study. The Oncologist, 26(3), e403\u2013e413.","journal-title":"The Oncologist"},{"key":"9834_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/2050-6511-15-47","volume":"15","author":"A Polk","year":"2014","unstructured":"Polk, A., Vistisen, K., Vaage-Nilsen, M., & Nielsen, D. L. (2014). A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacology & Toxicology, 15, 47.","journal-title":"BMC Pharmacology & Toxicology"},{"issue":"8","key":"9834_CR13","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.ctrv.2013.03.005","volume":"39","author":"A Polk","year":"2013","unstructured":"Polk, A., Vaage-Nilsen, M., Vistisen, K., & Nielsen, D. L. (2013). Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors. Cancer Treatment Reviews, 39(8), 974\u2013984.","journal-title":"Cancer Treatment Reviews"},{"issue":"4","key":"9834_CR14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.ccl.2019.07.004","volume":"37","author":"J Kanduri","year":"2019","unstructured":"Kanduri, J., More, L. A., Godishala, A., & Asnani, A. (2019). Fluoropyrimidine-associated cardiotoxicity. Cardiology Clinics, 37(4), 399\u2013405.","journal-title":"Cardiology Clinics"},{"issue":"3","key":"9834_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.toxlet.2014.03.018","volume":"227","author":"M Lamberti","year":"2014","unstructured":"Lamberti, M., Porto, S., Zappavigna, S., Addeo, E., Marra, M., Miraglia, N., Sannolo, N., Vanacore, D., Stiuso, P., & Caraglia, M. (2014). A mechanistic study on the cardiotoxicity of 5-fluorouracil in vitro and clinical and occupational perspectives. Toxicology Letters, 227(3), 151\u2013156.","journal-title":"Toxicology Letters"},{"issue":"1","key":"9834_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1080\/21548331.2018.1530831","volume":"47","author":"D Jain","year":"2019","unstructured":"Jain, D., & Aronow, W. (2019). Cardiotoxicity of cancer chemotherapy in clinical practice. Hospital Practice, 47(1), 6\u201315.","journal-title":"Hospital Practice"},{"key":"9834_CR17","unstructured":"Saif, W., Banchs, J., Kohne, C. (2022). Fluoropyrimidine-associated cardiotoxicity: incidence, clinical manifestations, mechanisms, and management. UpToDate Waltham, MA: Wolters Kluwer Health. Retrieved February 18, 2018, from https:\/\/www.uptodate.com\/login"},{"issue":"6","key":"9834_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11912-016-0521-1","volume":"18","author":"ME Layoun","year":"2016","unstructured":"Layoun, M. E., Wickramasinghe, C. D., Peralta, M. V., & Yang, E. H. (2016). Fluoropyrimidine-induced cardiotoxicity: Manifestations, mechanisms, and management. Current Oncology Reports, 18(6), 35.","journal-title":"Current Oncology Reports"},{"issue":"1","key":"9834_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00015385.2021.1873548","volume":"77","author":"E Teperikidis","year":"2022","unstructured":"Teperikidis, E., Boulmpou, A., Charalampidis, P., Tsavousoglou, C., Giannakoulas, G., Papadopoulos, C. E., & Vassilikos, V. (2022). 5-Fluorouracil, capecitabine and vasospasm: A scoping review of pathogenesis, management options and future research considerations. Acta Cardiologica, 77(1), 1\u201313.","journal-title":"Acta Cardiologica"},{"issue":"5","key":"9834_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jccase.2019.08.005","volume":"20","author":"S Moriyama","year":"2019","unstructured":"Moriyama, S., Yokoyama, T., Irie, K., Ito, M., Tsuchihashi, K., Fukata, M., Kusaba, H., Maruyama, T., & Akashi, K. (2019). Atrial fibrillation observed in a patient with esophageal cancer treated with fluorouracil. Journal of Cardiology Cases, 20(5), 183\u2013186.","journal-title":"Journal of Cardiology Cases"},{"issue":"6","key":"9834_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1159\/000495576","volume":"63","author":"M Sarocchi","year":"2018","unstructured":"Sarocchi, M., Arboscello, E., Ghigliotti, G., Murialdo, R., Bighin, C., Gualandi, F., Sicbaldi, V., Balbi, M., Brunelli, C., & Spallarossa, P. (2018). Ivabradine in cancer treatment-related left ventricular dysfunction. Chemotherapy, 63(6), 315\u2013320.","journal-title":"Chemotherapy"},{"issue":"5","key":"9834_CR22","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jaccao.2020.09.007","volume":"2","author":"NE Boutagy","year":"2020","unstructured":"Boutagy, N. E., Feher, A., Pfau, D., Liu, Z., Guerrera, N. M., Freeburg, L. A., Womack, S. J., Hoenes, A. C., Zeiss, C., Young, L. H., & Spinale, F. G. (2020). Dual angiotensin receptor-neprilysin inhibition with sacubitril\/valsartan attenuates systolic dysfunction in experimental doxorubicin-induced cardiotoxicity. JACC CardioOncology, 2(5), 774\u2013787.","journal-title":"JACC CardioOncology"},{"issue":"4","key":"9834_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/FPC.0b013e32833c6107","volume":"21","author":"CF Thorn","year":"2011","unstructured":"Thorn, C. F., Marsh, S., Carrillo, M. W., McLeod, H. L., Klein, T. E., & Altman, R. B. (2011). PharmGKB summary: Fluoropyrimidine pathways. Pharmacogenetics and Genomics, 21(4), 237.","journal-title":"Pharmacogenetics and Genomics"},{"issue":"1","key":"9834_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1158\/1078-0432.CCR-07-1225","volume":"14","author":"JL Yen-Revollo","year":"2008","unstructured":"Yen-Revollo, J. L., Goldberg, R. M., & McLeod, H. L. (2008). Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 14(1), 8\u201313.","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"8","key":"9834_CR25","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","volume":"34","author":"M Miwa","year":"1998","unstructured":"Miwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998). Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. European Journal of Cancer, 34(8), 1274\u20131281.","journal-title":"European Journal of Cancer"},{"issue":"5","key":"9834_CR26","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003). 5-fluorouracil: Mechanisms of action and clinical strategies. Nature Reviews Cancer, 3(5), 330\u2013338.","journal-title":"Nature Reviews Cancer"},{"issue":"2","key":"9834_CR27","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2174\/0929867053363432","volume":"12","author":"WH Gmeiner","year":"2005","unstructured":"Gmeiner, W. H. (2005). Novel chemical strategies for thymidylate synthase inhibition. Current Medicinal Chemistry, 12(2), 191\u2013202.","journal-title":"Current Medicinal Chemistry"},{"issue":"4","key":"9834_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1000091","volume":"7","author":"C Kunz","year":"2009","unstructured":"Kunz, C., Focke, F., Saito, Y., Schuermann, D., Lettieri, T., Selfridge, J., & Sch\u00e4r, P. (2009). Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil. PLoS Biology, 7(4), e1000091.","journal-title":"PLoS Biology"},{"key":"9834_CR29","doi-asserted-by":"publisher","first-page":"175883591878014","DOI":"10.1177\/1758835918780140","volume":"10","author":"JD Sara","year":"2018","unstructured":"Sara, J. D., Kaur, J., Khodadadi, R., Rehman, M., Lobo, R., Chakrabarti, S., Herrmann, J., Lerman, A., & Grothey, A. (2018). 5-fluorouracil and cardiotoxicity: A review. Therapeutic Advances in Medical Oncology, 10, 1758835918780140.","journal-title":"Therapeutic Advances in Medical Oncology"},{"issue":"5","key":"9834_CR30","doi-asserted-by":"publisher","first-page":"453","DOI":"10.5603\/CJ.2012.0084","volume":"19","author":"MF Sorrentino","year":"2012","unstructured":"Sorrentino, M. F., Kim, J., Foderaro, A. E., & Truesdell, A. G. (2012). 5-fluorouracil induced cardiotoxicity: Review of the literature. Cardiology Journal, 19(5), 453\u2013457.","journal-title":"Cardiology Journal"},{"issue":"8","key":"9834_CR31","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3390\/molecules13081551","volume":"13","author":"N Zhang","year":"2008","unstructured":"Zhang, N., Yin, Y., Xu, S.-J., & Chen, W.-S. (2008). 5-fluorouracil: Mechanisms of resistance and reversal strategies. Molecules, 13(8), 1551\u20131569.","journal-title":"Molecules"},{"issue":"4","key":"9834_CR32","first-page":"801","volume":"18","author":"H Wada","year":"2007","unstructured":"Wada, H., Nagano, H., Yamamoto, H., Arai, I., Ota, H., Nakamura, M., Damdinsuren, B., Noda, T., Marubashi, S., Miyamoto, A., & Takeda, Y. (2007). Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins. Oncology Reports, 18(4), 801\u2013809.","journal-title":"Oncology Reports"},{"issue":"2","key":"9834_CR33","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4161\/cbt.4.2.1476","volume":"4","author":"A Carbone","year":"2005","unstructured":"Carbone, A., Rodeck, U., Mauri, F. A., Sozzi, M., Gaspari, F., Smirne, C., Prati, A., Addeo, A., Novarino, A., Robecchi, A., & Bertetto, O. (2005). Human pancreatic carcinoma cells secrete bioactive interleukin-18 after treatment with 5-fluorouracil: implications for anti-tumor immune response. Cancer Biology & Therapy, 4(2), 239\u2013249.","journal-title":"Cancer Biology & Therapy"},{"issue":"8","key":"9834_CR34","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.4161\/cbt.7.8.6302","volume":"7","author":"JY Chan","year":"2008","unstructured":"Chan, J. Y., Phoo, M. S., Clement, M.-V., Pervaiz, S., & Lee, S. C. (2008). Resveratrol displays converse dose-related effects on 5-fluorouracil-evoked colon cancer cell apoptosis: The roles of caspase-6 and p53. Cancer Biology & Therapy, 7(8), 1305\u20131312.","journal-title":"Cancer Biology & Therapy"},{"issue":"2","key":"9834_CR35","volume":"3","author":"SA Thomas","year":"2016","unstructured":"Thomas, S. A., Grami, Z., Mehta, S., & Patel, K. (2016). Adverse effects of 5-fluorouracil: Focus on rare side effects. Cancer Cell Microenviron, 3(2), e1266.","journal-title":"Cancer Cell Microenviron"},{"key":"9834_CR36","doi-asserted-by":"crossref","unstructured":"Lamberti, M., Giovane, G., Garzillo, E.M., Avino, F., Feola, A., Porto, S., Tombolini, V., Di Domenico, M. (2014). Animal models in studies of cardiotoxicity side effects from antiblastic drugs in patients and occupational exposed workers. BioMed Research International","DOI":"10.1155\/2014\/240642"},{"issue":"1","key":"9834_CR37","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/1748-717X-7-212","volume":"7","author":"F Steger","year":"2012","unstructured":"Steger, F., Hautmann, M. G., & K\u00f6lbl, O. (2012). 5-FU-induced cardiac toxicity\u2014an underestimated problem in radiooncology? Radiation Oncology, 7(1), 212.","journal-title":"Radiation Oncology"},{"issue":"1","key":"9834_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40959-019-0048-3","volume":"5","author":"C Yuan","year":"2019","unstructured":"Yuan, C., Parekh, H., Allegra, C., George, T. J., & Starr, J. S. (2019). 5-FU induced cardiotoxicity: Case series and review of the literature. Cardio-Oncology, 5(1), 13.","journal-title":"Cardio-Oncology"},{"issue":"1","key":"9834_CR39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/CAD.0b013e3283165f27","volume":"20","author":"JR Dalzell","year":"2009","unstructured":"Dalzell, J. R., & Samuel, L. M. (2009). The spectrum of 5-fluorouracil cardiotoxicity. Anti-Cancer Drugs, 20(1), 79\u201380.","journal-title":"Anti-Cancer Drugs"},{"key":"9834_CR40","doi-asserted-by":"publisher","first-page":"10197","DOI":"10.2147\/OTT.S264156","volume":"13","author":"MW Saif","year":"2020","unstructured":"Saif, M. W. (2020). Alternative treatment options in patients with colorectal cancer who encounter fluoropyrimidine-induced cardiotoxicity. OncoTargets and Therapy, 13, 10197\u201310206.","journal-title":"OncoTargets and Therapy"},{"issue":"1","key":"9834_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/187152506775268785","volume":"4","author":"P Alter","year":"2006","unstructured":"Alter, P., Herzum, M., Soufi, M., Schaefer, J., & Maisch, B. (2006). Cardiotoxicity of 5-fluorouracil. Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Cardiovascular & Hematological Agents), 4(1), 1\u20135.","journal-title":"Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Cardiovascular & Hematological Agents)"},{"issue":"4","key":"9834_CR42","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1200\/JCO.1989.7.4.509","volume":"7","author":"S Rezkalla","year":"1989","unstructured":"Rezkalla, S., Kloner, R. A., Ensley, J., Al-Sarraf, M., Revels, S., Olivenstein, A., Bhasin, S., Kerpel-Fronious, S., & Turi, Z. G. (1989). Continuous ambulatory ECG monitoring during fluorouracil therapy: A prospective study. Journal of Clinical Oncology, 7(4), 509\u2013514.","journal-title":"Journal of Clinical Oncology"},{"key":"9834_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2018.02.002","volume":"124","author":"I Depetris","year":"2018","unstructured":"Depetris, I., Marino, D., Bonzano, A., Cagnazzo, C., Filippi, R., Aglietta, M., & Leone, F. (2018). Fluoropyrimidine-induced cardiotoxicity. Critical Reviews in Oncology\/Hematology, 124, 1\u201310.","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"4","key":"9834_CR44","first-page":"1531","volume":"34","author":"P Papanastasopoulos","year":"2014","unstructured":"Papanastasopoulos, P., & Stebbing, J. (2014). Molecular basis of 5-fluorouracil-related toxicity: Lessons from clinical practice. Anticancer Research, 34(4), 1531\u20131535.","journal-title":"Anticancer Research"},{"issue":"1","key":"9834_CR45","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/0003319716637516","volume":"68","author":"T Turan","year":"2017","unstructured":"Turan, T., Agac, M. T., Aykan, A. \u00c7., Kul, S., Aky\u00fcz, A. R., G\u00f6kdeniz, T., G\u00fcl, \u0130, Cengiz, E., Boyac\u0131, F., Erkan, H., & Akdemir, R. (2017). Usefulness of heart-type fatty acid-binding protein and myocardial performance index for early detection of 5-fluorouracil cardiotoxicity. Angiology, 68(1), 52\u201358.","journal-title":"Angiology"},{"issue":"2","key":"9834_CR46","first-page":"89","volume":"14","author":"JH Chong","year":"2019","unstructured":"Chong, J. H., & Ghosh, A. K. (2019). Coronary artery vasospasm induced by 5-fluorouracil: Proposed mechanisms, existing management options and future directions. Interventional Cardiology Review, 14(2), 89.","journal-title":"Interventional Cardiology Review"},{"key":"9834_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.847012","volume":"9","author":"MB Morelli","year":"2022","unstructured":"Morelli, M. B., Bongiovanni, C., Da Pra, S., Miano, C., Sacchi, F., Lauriola, M., & D\u2019Uva, G. (2022). Cardiotoxicity of anticancer drugs: Molecular mechanisms and strategies for cardioprotection. Frontiers in Cardiovascular Medicine, 9, 847012.","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"4","key":"9834_CR48","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11864-020-0719-1","volume":"21","author":"T Shiga","year":"2020","unstructured":"Shiga, T., & Hiraide, M. (2020). Cardiotoxicities of 5-fluorouracil and other fluoropyrimidines. Current Treatment Options in Oncology, 21(4), 27.","journal-title":"Current Treatment Options in Oncology"},{"issue":"1","key":"9834_CR49","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/molecules14010053","volume":"14","author":"I Spasojevi\u0107","year":"2008","unstructured":"Spasojevi\u0107, I., Jeli\u0107, S., Zakrzewska, J., & Ba\u010di\u0107, G. (2008). Decreased oxygen transfer capacity of erythrocytes as a cause of 5-fluorouracil related ischemia. Molecules, 14(1), 53\u201367.","journal-title":"Molecules"},{"issue":"4","key":"9834_CR50","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00280-005-0178-1","volume":"58","author":"SA Jensen","year":"2006","unstructured":"Jensen, S. A., & S\u00f8rensen, J. B. (2006). Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemotherapy and Pharmacology, 58(4), 487\u2013493.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"9834_CR51","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","volume":"134","author":"C Kosmas","year":"2008","unstructured":"Kosmas, C., Kallistratos, M. S., Kopterides, P., Syrios, J., Skopelitis, H., Mylonakis, N., Karabelis, A., & Tsavaris, N. (2008). Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. Journal of Cancer Research and Clinical Oncology, 134, 75\u201382.","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"5","key":"9834_CR52","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/j.1742-1241.2007.01323.x","volume":"61","author":"U Yilmaz","year":"2007","unstructured":"Yilmaz, U., Oztop, I., Ciloglu, A., Okan, T., Tekin, U., Yaren, A., Somali, I., Alacacioglu, A., & Kirimli, O. (2007). 5-fluorouracil increases the number and complexity of premature complexes in the heart: A prospective study using ambulatory ECG monitoring. International Journal of Clinical Practice, 61(5), 795\u2013801.","journal-title":"International Journal of Clinical Practice"},{"issue":"10","key":"9834_CR53","volume":"14","author":"LC Medepalli","year":"2022","unstructured":"Medepalli, L. C., Mahmood, T. S., Liberman, H., Medepalli, A. M., & Bagwell, T. W. (2022). Diagnosis and management of a patient with 5-fluorouracil-induced ST elevation and nonsustained ventricular tachycardia as a late presentation of cardiotoxicity and successful 5-fluorouracil rechallenge. Cureus, 14(10), e30489.","journal-title":"Cureus"},{"key":"9834_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11886-021-01441-2","volume":"23","author":"LA More","year":"2021","unstructured":"More, L. A., Lane, S., & Asnani, A. (2021). 5-FU cardiotoxicity: Vasospasm, myocarditis, and sudden death. Current Cardiology Reports, 23, 1\u20138.","journal-title":"Current Cardiology Reports"},{"issue":"2","key":"9834_CR55","first-page":"329","volume":"2","author":"I Raber","year":"2020","unstructured":"Raber, I., Frazer, M. B., Zerillo, J. A., & Asnani, A. (2020). Uridine triacetate for severe fluoropyrimidine cardiotoxicity in a patient with thymidylate synthase gene variants. Cardio Oncology, 2(2), 329\u2013332.","journal-title":"Cardio Oncology"},{"issue":"1","key":"9834_CR56","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00280-011-1669-x","volume":"69","author":"SA Jensen","year":"2012","unstructured":"Jensen, S. A., & S\u00f8rensen, J. B. (2012). 5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity. Cancer Chemotherapy and Pharmacology, 69(1), 57\u201364.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"4","key":"9834_CR57","first-page":"301","volume":"59","author":"D Di Lisi","year":"2011","unstructured":"Di Lisi, D., Bonura, F., Macaione, F., Cuttitta, F., Peritore, A., Meschisi, M., Novo, G., D\u2019Alessandro, N., & Novo, S. (2011). Chemotherapy-induced cardiotoxicity: Role of the conventional echocardiography and the tissue Doppler. Minerva Cardioangiologica, 59(4), 301\u2013308.","journal-title":"Minerva Cardioangiologica"},{"issue":"2","key":"9834_CR58","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000072334","volume":"65","author":"A Wacker","year":"2003","unstructured":"Wacker, A., Lersch, C., Scherpinski, U., Reindl, L., & Seyfarth, M. (2003). High incidence of angina pectoris in patients treated with 5-fluorouracil. Oncology, 65(2), 108\u2013112.","journal-title":"Oncology"},{"issue":"2","key":"9834_CR59","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1517\/14740330902733961","volume":"8","author":"MW Saif","year":"2009","unstructured":"Saif, M. W., Shah, M. M., & Shah, A. R. (2009). Fluoropyrimidine-associated cardiotoxicity: Revisited. Expert Opinion on Drug Safety, 8(2), 191\u2013202.","journal-title":"Expert Opinion on Drug Safety"},{"key":"9834_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40959-019-0048-3","volume":"5","author":"C Yuan","year":"2019","unstructured":"Yuan, C., Parekh, H., Allegra, C., George, T. J., & Starr, J. S. (2019). 5-FU induced cardiotoxicity: Case series and review of the literature. Cardio-Oncology, 5, 1\u20137.","journal-title":"Cardio-Oncology"},{"issue":"3","key":"9834_CR61","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/annonc\/mdf108","volume":"13","author":"E Van Cutsem","year":"2002","unstructured":"Van Cutsem, E., Hoff, P., Blum, J., Abt, M., & Osterwalder, B. (2002). Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Annals of Oncology, 13(3), 484\u2013485.","journal-title":"Annals of Oncology"},{"issue":"2","key":"9834_CR62","doi-asserted-by":"publisher","first-page":"111","DOI":"10.15420\/ahhj.2010.8.2.111","volume":"8","author":"R Tajik","year":"2010","unstructured":"Tajik, R., Saadat, H., Taherkhani, M., & Movahed, M. R. (2010). Angina induced by 5-fluorouracil infusion in a patient with normal coronaries. American Heart Hospital Journal, 8(2), 111\u2013112.","journal-title":"American Heart Hospital Journal"},{"key":"9834_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-016-0521-1","volume":"18","author":"ME Layoun","year":"2016","unstructured":"Layoun, M. E., Wickramasinghe, C. D., Peralta, M. V., & Yang, E. H. (2016). Fluoropyrimidine-induced cardiotoxicity: Manifestations, mechanisms, and management. Current Oncology Reports, 18, 1\u201312.","journal-title":"Current Oncology Reports"},{"issue":"6","key":"9834_CR64","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1159\/000227226","volume":"50","author":"SS Akhtar","year":"1993","unstructured":"Akhtar, S. S., Salim, K. P., & Bano, Z. A. (1993). Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: A prospective study. Oncology, 50(6), 441\u2013444.","journal-title":"Oncology"},{"issue":"7","key":"9834_CR65","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/S0300-8932(02)76696-7","volume":"55","author":"J Luj\u00e1n","year":"2002","unstructured":"Luj\u00e1n, J., Garc\u00eda de Burgos, F., Jord\u00e1n, A., Garc\u00eda, M., Reyes, F., & Espinosa, M. D. (2002). Angina related to 5-fluorouracil. Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition), 55(7), 764\u2013767.","journal-title":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"},{"issue":"3","key":"9834_CR66","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11886-021-01441-2","volume":"23","author":"LA More","year":"2021","unstructured":"More, L. A., Lane, S., & Asnani, A. (2021). 5-FU cardiotoxicity: Vasospasm, myocarditis, and sudden death. Current Cardiology Reports, 23(3), 17.","journal-title":"Current Cardiology Reports"},{"issue":"4","key":"9834_CR67","first-page":"531","volume":"27","author":"MW Saif","year":"2013","unstructured":"Saif, M. W., Garcon, M. C., Rodriguez, G., & Rodriguez, T. (2013). Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: A case series. In vivo (Athens, Greece), 27(4), 531\u2013534.","journal-title":"In vivo (Athens, Greece)"},{"issue":"2","key":"9834_CR68","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0385-8146(00)00112-7","volume":"28","author":"A Tutkun","year":"2001","unstructured":"Tutkun, A., \u0130nanl\u0131, S., Caymaz, O., Ayano\u011flu, E., & Duman, D. (2001). Cardiotoxicity of 5-flourouracil: Two case reports. Auris, Nasus, Larynx, 28(2), 193\u2013196.","journal-title":"Auris, Nasus, Larynx"},{"issue":"3","key":"9834_CR69","doi-asserted-by":"publisher","first-page":"e606","DOI":"10.1634\/theoncologist.2019-0762","volume":"25","author":"I Raber","year":"2019","unstructured":"Raber, I., Warack, S., Kanduri, J., Pribish, A., Godishala, A., Abovich, A., Orbite, A., Dommaraju, S., Frazer, M., Peters, M. L., & Asnani, A. (2019). Fluoropyrimidine-associated cardiotoxicity: A retrospective case-control study. The Oncologist, 25(3), e606\u2013e609.","journal-title":"The Oncologist"},{"issue":"4","key":"9834_CR70","doi-asserted-by":"publisher","first-page":"e0265767","DOI":"10.1371\/journal.pone.0265767","volume":"17","author":"A Zafar","year":"2022","unstructured":"Zafar, A., Drobni, Z. D., Lei, M., Gongora, C. A., Quinaglia, T., Lou, U. Y., Mosarla, R., Murphy, S. P., Jones-O\u2019Connor, M., Mahmood, A., & Hartmann, S. (2022). The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm. PLoS ONE, 17(4), e0265767.","journal-title":"PLoS ONE"},{"issue":"2","key":"9834_CR71","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/cncr.30321","volume":"123","author":"WW Ma","year":"2017","unstructured":"Ma, W. W., Saif, M. W., El-Rayes, B. F., Fakih, M. G., Cartwright, T. H., Posey, J. A., King, T. R., von Borstel, R. W., & Bamat, M. K. (2017). Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. Cancer, 123(2), 345\u2013356.","journal-title":"Cancer"},{"issue":"4","key":"9834_CR72","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jaccao.2020.06.012","volume":"2","author":"A Padegimas","year":"2020","unstructured":"Padegimas, A., & Carver, J. R. (2020). How to diagnose and manage patients with fluoropyrimidine-induced chest pain. JACC CardioOncology, 2(4), 650\u2013654.","journal-title":"JACC CardioOncology"},{"key":"9834_CR73","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.phrs.2015.10.018","volume":"103","author":"CG Mihos","year":"2016","unstructured":"Mihos, C. G., Krishna, R. K., Kherada, N., Larrauri-Reyes, M., Tolentino, A., & Santana, O. (2016). The use of ranolazine in non-anginal cardiovascular disorders: A review of current data and ongoing randomized clinical trials. Pharmacological Research, 103, 49\u201355.","journal-title":"Pharmacological Research"},{"key":"9834_CR74","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fcvm.2020.00035","volume":"7","author":"A Murabito","year":"2020","unstructured":"Murabito, A., Hirsch, E., & Ghigo, A. (2020). Mechanisms of anthracycline-induced cardiotoxicity: Is mitochondrial dysfunction the answer? Frontiers in Cardiovascular Medicine, 7, 35.","journal-title":"Frontiers in Cardiovascular Medicine"},{"key":"9834_CR75","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.phrs.2013.11.001","volume":"79","author":"F Corradi","year":"2014","unstructured":"Corradi, F., Paolini, L., & De Caterina, R. (2014). Ranolazine in the prevention of anthracycline cardiotoxicity. Pharmacological research., 79, 88\u2013102.","journal-title":"Pharmacological research."},{"issue":"3","key":"9834_CR76","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1124\/jpet.113.204057","volume":"346","author":"G Minotti","year":"2013","unstructured":"Minotti, G. (2013). Pharmacology at work for cardio-oncology: Ranolazine to treat early cardiotoxicity induced by antitumor drugs. Journal of Pharmacology and Experimental Therapeutics, 346(3), 343\u2013349.","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"21","key":"9834_CR77","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1111\/bph.14025","volume":"174","author":"DJ Grieve","year":"2017","unstructured":"Grieve, D. J., & Davidson, S. M. (2017). New insights into cardiotoxicity caused by chemotherapeutic agents. British Journal of Pharmacology, 174(21), 3675\u20133676.","journal-title":"British Journal of Pharmacology"},{"issue":"21","key":"9834_CR78","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1111\/bph.13791","volume":"174","author":"D Cappetta","year":"2017","unstructured":"Cappetta, D., Esposito, G., Coppini, R., Piegari, E., Russo, R., Ciuffreda, L. P., Rivellino, A., Santini, L., Rafaniello, C., Scavone, C., & Rossi, F. (2017). Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction. British Journal of Pharmacology, 174(21), 3696\u20133712.","journal-title":"British Journal of Pharmacology"},{"issue":"15_suppl","key":"9834_CR79","doi-asserted-by":"publisher","first-page":"e15613","DOI":"10.1200\/JCO.2021.39.15_suppl.e15613","volume":"39","author":"A Kasi","year":"2021","unstructured":"Kasi, A., Gaudel, P., Bennett, J., Al-Rajabi, RMd. T., Saeed, A., Baranda, J. C., Sun, W., & Porter, C. B. (2021). A novel outpatient regimen in management of fluoropyrimidine-induced cardiotoxicity. Journal of Clinical Oncology, 39(15_suppl), e15613.","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"9834_CR80","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1007\/s10787-022-01082-z","volume":"30","author":"HM Al-Kuraishy","year":"2022","unstructured":"Al-Kuraishy, H. M., Issa, H. K., Al-Gareeb, A. I., El-Bouseary, M. M., Youssef, A., Abdelaziz, A. S., Khalifa, H. A., & Batiha, G. E. (2022). The role of ivabradine in doxorubicin-induced cardiotoxicity: exploring of underlying argument. Inflammopharmacology, 30(6), 2441\u20132446.","journal-title":"Inflammopharmacology"},{"issue":"1","key":"9834_CR81","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/FJC.0000000000000586","volume":"72","author":"AE El-Naggar","year":"2018","unstructured":"El-Naggar, A. E., El-Gowilly, S. M., & Sharabi, F. M. (2018). Possible Ameliorative effect of ivabradine on the autonomic and left ventricular dysfunction induced by doxorubicin in male rats. Journal of Cardiovascular Pharmacology, 72(1), 22\u201331.","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"3","key":"9834_CR82","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ijcard.2014.07.272","volume":"176","author":"C de Gregorio","year":"2014","unstructured":"de Gregorio, C., Potenza, G., & Ferraro, G. (2014). Effectiveness of the combination therapy with lisinopril, ivabradine and multivitamin supplementation in anthracycline-induced severe cardiotoxicity. International Journal of Cardiology, 176(3), 1374\u20131376.","journal-title":"International Journal of Cardiology"},{"issue":"9","key":"9834_CR83","doi-asserted-by":"publisher","first-page":"700","DOI":"10.2459\/JCM.0b013e328332e873","volume":"11","author":"C Lestuzzi","year":"2010","unstructured":"Lestuzzi, C., Crivellari, D., Rigo, F., Viel, E., & Meneguzzo, N. (2010). Capecitabine cardiac toxicity presenting as effort angina: A case report. Journal of Cardiovascular Medicine, 11(9), 700\u2013703.","journal-title":"Journal of Cardiovascular Medicine"},{"issue":"3","key":"9834_CR84","first-page":"304","volume":"32","author":"A Sikandar","year":"2020","unstructured":"Sikandar, A., Farhat, K., Afzal, A., Ajmal, K., Laeeq, M., & Khokhar, A. (2020). Protective effects of trimetazidine against doxorubicin-induced cardiotoxicity and hepatotoxicity in mice. Journal of Ayub Medical College Abbottabad, 32(3), 304\u2013309.","journal-title":"Journal of Ayub Medical College Abbottabad"},{"issue":"5","key":"9834_CR85","first-page":"232","volume":"22","author":"L Zhao","year":"2019","unstructured":"Zhao, L. (2019). Protective effects of trimetazidine and coenzyme Q10 on cisplatin-induced cardiotoxicity by alleviating oxidative stress and mitochondrial dysfunction. Anatolian Journal of Cardiology, 22(5), 232\u2013239.","journal-title":"Anatolian Journal of Cardiology"},{"issue":"6","key":"9834_CR86","doi-asserted-by":"publisher","first-page":"S292","DOI":"10.1097\/00004872-198900076-00142","volume":"7","author":"G Leonetti","year":"1989","unstructured":"Leonetti, G., Fruscio, M., Gradnik, R., Chianca, R., Bolla, G. B., Prandi, P., & Zanchetti, A. (1989). Nicorandil, a new vasodilator drug, in patients with essential hypertension. Journal of hypertension Supplement: Official Journal of the International Society of Hypertension, 7(6), S292\u2013S293.","journal-title":"Journal of hypertension Supplement: Official Journal of the International Society of Hypertension"},{"issue":"3","key":"9834_CR87","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/bcpt.12078","volume":"113","author":"IT Abdel-Raheem","year":"2013","unstructured":"Abdel-Raheem, I. T., Taye, A., & Abouzied, M. M. (2013). Cardioprotective effects of nicorandil, a mitochondrial potassium channel opener against doxorubicin-induced cardiotoxicity in rats. Basic & Clinical Pharmacology & Toxicology, 113(3), 158\u2013166.","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"key":"9834_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119607","volume":"277","author":"C-W Kim","year":"2021","unstructured":"Kim, C.-W., & Choi, K.-C. (2021). Effects of anticancer drugs on the cardiac mitochondrial toxicity and their underlying mechanisms for novel cardiac protective strategies. Life Sciences, 277, 119607.","journal-title":"Life Sciences"},{"issue":"2","key":"9834_CR89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172803","volume":"12","author":"MC Asensio-L\u00f3pez","year":"2017","unstructured":"Asensio-L\u00f3pez, M. C., Soler, F., Pascual-Figal, D., Fernandez-Belda, F., & Lax, A. (2017). Doxorubicin-induced oxidative stress: The protective effect of nicorandil on HL-1 cardiomyocytes. PLoS ONE, 12(2), e0172803.","journal-title":"PLoS ONE"},{"issue":"3","key":"9834_CR90","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1253\/circj.CJ-08-0843","volume":"73","author":"Y Eguchi","year":"2009","unstructured":"Eguchi, Y., Takahari, Y., Higashijima, N., Ishizuka, N., Tamura, N., Kawamura, Y., & Ishida, H. (2009). Nicorandil attenuates FeCl(3)-induced thrombus formation through the inhibition of reactive oxygen species production. Circulation Journal: Official Journal of the Japanese Circulation Society, 73(3), 554\u2013561.","journal-title":"Circulation Journal: Official Journal of the Japanese Circulation Society"},{"issue":"5","key":"9834_CR91","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1159\/000209336","volume":"76","author":"V Le Brun-Ly","year":"2009","unstructured":"Le Brun-Ly, V., Martin, J., Venat-Bouvet, L., Darodes, N., Labourey, J.-L., Genet, D., & Tubiana-Mathieu, N. (2009). Cardiac toxicity with capecitabine, vinorelbine and trastuzumab therapy: Case report and review of fluoropyrimidine-related cardiotoxicity. Oncology, 76(5), 322\u2013325.","journal-title":"Oncology"},{"issue":"1","key":"9834_CR92","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10557-021-07252-5","volume":"37","author":"Y Wan","year":"2023","unstructured":"Wan, Y., He, B., Zhu, D., Wang, L., Huang, R., Wang, S., Wang, C., Zhang, M., Ma, L., & Gao, F. (2023). Nicorandil ameliorates doxorubicin-induced cardiotoxicity in rats, as evaluated by 7\u00a0T cardiovascular magnetic resonance imaging. Cardiovascular Drugs and Therapy, 37(1), 39\u201351.","journal-title":"Cardiovascular Drugs and Therapy"},{"issue":"1","key":"9834_CR93","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/BF02867674","volume":"18","author":"N Singh","year":"2003","unstructured":"Singh, N., & Kumar, R. (2003). Effect of nicorandil and amlodipine on bio-chemical parameters during isoproterenol induced myocardial necrosis in rats. Indian Journal of Clinical Biochemistry: IJCB, 18(1), 99\u2013102.","journal-title":"Indian Journal of Clinical Biochemistry: IJCB"},{"issue":"1","key":"9834_CR94","first-page":"19","volume":"4","author":"T Omland","year":"2022","unstructured":"Omland, T., Heck, S. L., & Gulati, G. (2022). The role of cardioprotection in cancer therapy cardiotoxicity JACC: CardioOncology state-of-the-art review. JACC: CardioOncology, 4(1), 19\u201337.","journal-title":"JACC: CardioOncology"},{"issue":"12","key":"9834_CR95","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1002\/ejhf.1985","volume":"22","author":"JL Zamorano","year":"2020","unstructured":"Zamorano, J. L., Gottfridsson, C., Asteggiano, R., Atar, D., Badimon, L., Bax, J. J., Cardinale, D., Cardone, A., Feijen, E. A., Ferdinandy, P., & L\u00f3pez-Fern\u00e1ndez, T. (2020). The cancer patient and cardiology. European Journal of Heart Failure, 22(12), 2290\u20132309.","journal-title":"European Journal of Heart Failure"},{"issue":"2","key":"9834_CR96","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jaccao.2020.02.017","volume":"2","author":"M Camilli","year":"2020","unstructured":"Camilli, M., Del Buono, M. G., Crea, F., & Minotti, G. (2020). Acute heart failure 29 years after treatment for childhood cancer. JACC CardioOncology, 2(2), 316\u2013319.","journal-title":"JACC CardioOncology"},{"issue":"5","key":"9834_CR97","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1002\/ehf2.13547","volume":"8","author":"S Giovinazzo","year":"2021","unstructured":"Giovinazzo, S., Carmisciano, L., Toma, M., Benenati, S., Tomasoni, D., Sormani, M. P., et al. (2021). Sacubitril\/valsartan in real-life European patients with heart failure and reduced ejection fraction: A systematic review and meta-analysis. ESC Heart Fail, 8(5), 3547\u20133556.","journal-title":"ESC Heart Fail."},{"issue":"6","key":"9834_CR98","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1002\/ehf2.13760","volume":"8","author":"L Stretti","year":"2021","unstructured":"Stretti, L., Zippo, D., Coats, A. J. S., Anker, M. S., von Haehling, S., Metra, M., & Tomasoni, D. (2021). A year in heart failure: An update of recent findings. ESC Heart Failure, 8(6), 4370\u20134393.","journal-title":"ESC Heart Failure"},{"issue":"2","key":"9834_CR99","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/ehf2.12627","volume":"7","author":"A Mart\u00edn-Garcia","year":"2020","unstructured":"Mart\u00edn-Garcia, A., L\u00f3pez-Fern\u00e1ndez, T., Mitroi, C., Chaparro-Mu\u00f1oz, M., Moliner, P., Martin-Garcia, A. C., Martinez-Monzonis, A., Castro, A., Lopez-Sendon, J. L., & Sanchez, P. L. (2020). Effectiveness of sacubitril-valsartan in cancer patients with heart failure. ESC Heart Fail, 7(2), 763\u2013767.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"9834_CR100","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/ejhf.2076","volume":"23","author":"MF Piepoli","year":"2021","unstructured":"Piepoli, M. F., Hussain, R. I., Comin-Colet, J., Dosantos, R., Ferber, P., Jaarsma, T., & Edelmann, F. (2021). OUTSTEP-HF: Randomised controlled trial comparing short-term effects of sacubitril\/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction. European Journal of Heart Failure, 23(1), 127\u2013135.","journal-title":"European Journal of Heart Failure"},{"issue":"1","key":"9834_CR101","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40959-020-00078-4","volume":"6","author":"V Gregorietti","year":"2020","unstructured":"Gregorietti, V., Fernandez, T. L., Costa, D., Chahla, E. O., & Daniele, A. J. (2020). Use of Sacubitril\/valsartan in patients with cardio toxicity and heart failure due to chemotherapy. Cardio-oncology (London, England), 6(1), 24.","journal-title":"Cardio-oncology (London, England)"},{"issue":"4","key":"9834_CR102","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s12012-020-09562-w","volume":"20","author":"JD Allison","year":"2020","unstructured":"Allison, J. D., Tanavin, T., Yang, Y., Birnbaum, G., & Khalid, U. (2020). Various manifestations of 5-fluorouracil cardiotoxicity: A multicenter case series and review of literature. Cardiovascular Toxicology, 20(4), 437\u2013442.","journal-title":"Cardiovascular Toxicology"},{"issue":"12","key":"9834_CR103","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.5306\/wjco.v11.i12.1008","volume":"11","author":"AL Deac","year":"2020","unstructured":"Deac, A. L., Burz, C. C., Bocsan, I. C., & Buzoianu, A. D. (2020). Fluoropyrimidine-induced cardiotoxicity. World Journal of Clinical Oncology, 11(12), 1008\u20131017.","journal-title":"World Journal of Clinical Oncology"},{"issue":"19","key":"9834_CR104","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.3390\/jcm10194426","volume":"10","author":"M Jurczyk","year":"2021","unstructured":"Jurczyk, M., Kr\u00f3l, M., Midro, A., Kurnik-\u0141ucka, M., Poniatowski, A., & Gil, K. (2021). Cardiotoxicity of fluoropyrimidines: Epidemiology, mechanisms, diagnosis, and management. Journal of Clinical Medicine, 10(19), 4426.","journal-title":"Journal of Clinical Medicine"},{"key":"9834_CR105","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2021.45","volume":"17","author":"S Tyebally","year":"2022","unstructured":"Tyebally, S., Ghose, A., Chen, D. H., Abiodun, A. T., & Ghosh, A. K. (2022). Chest pain in the cancer patient. European Cardiology, 17, e15.","journal-title":"European Cardiology"},{"issue":"7","key":"9834_CR106","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s11912-022-01256-6","volume":"24","author":"LB Vater","year":"2022","unstructured":"Vater, L. B., Lefebvre, B., Turk, A., & Clasen, S. C. (2022). Fluoropyrimidine cardiotoxicity: Incidence, outcomes, and safety of rechallenge. Current Oncology Reports, 24(7), 943\u2013950.","journal-title":"Current Oncology Reports"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-024-09834-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-024-09834-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-024-09834-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T05:26:44Z","timestamp":1709011604000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-024-09834-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":106,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["9834"],"URL":"https:\/\/doi.org\/10.1007\/s12012-024-09834-9","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"21 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}